chlorisobutylamide

Chlorisobutylamide is a small molecule antiepileptic drug candidate developed by the Beijing Bolivikon Pharmaceutical Research Institute. It has been investigated in Phase 1 clinical trials in China, specifically in a randomized, double-blind, placebo-controlled, parallel-group single oral dose tolerance study (CTR20132378) conducted in healthy Chinese adults. The study was designed to evaluate the safety, tolerability, and maximum tolerated dose of the compound. Chlorisobutylamide is intended for the treatment of epilepsy, and its chemical structure suggests it may function through the modulation of voltage-gated ion channels, a common mechanism for anticonvulsant amides, although its specific molecular targets have not been extensively detailed in public clinical disclosures.

Other names

氯异丁酰胺